Roche builds long-term case for Evrysdi with 2-year SMA data; ExeVir nets $50M Series A for llama-derived Covid antibody
At the two-year mark, Roche’s Evrysdi (risdiplam) either maintained or improved motor function from a one-year check-up in patients aged 2 to 25 with Types 2 or 3 spinal muscular atrophy, the Swiss drugmaker said Tuesday.
Even better, Evrysdi showed no new long-term safety signals, and patients in the second year of treatment actually posted fewer severe side effects than in the first year, Roche said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
